GOLDSTREAM INV (01328) releases annual performance results with a net loss attributable to shareholders of 8.782 million Hong Kong dollars, a year-on-year change from profit to loss.
Golden Spring Investment (01328) announced its annual performance for the year ending December 31, 2025. The group recorded a net gain of approximately 80.297 million Hong Kong dollars from financial assets and liabilities measured at fair value that are recognized in profit or loss, representing a year-on-year increase of 13.71%. Shareholders' share of losses amounted to 8.782 million Hong Kong dollars, compared to a profit in the previous year, with a basic loss per share of 3.42 Hong Kong cents.
GOLDSTREAM INV(01328) released its annual results for the year ending December 31, 2025. The Group recorded a net fair value gain on financial assets and liabilities at fair value through profit or loss of approximately 80.29 million Hong Kong dollars, a year-on-year increase of 13.71%; shareholders' loss attributable to owners was 8.782 million Hong Kong dollars, a year-on-year loss compared to profit; basic loss per share was 3.42 Hong Kong cents.
Related Articles

SSY GROUP(02005): Upatinib has been approved by the China Food and Drug Administration for registration as an active pharmaceutical ingredient for use in marketed preparations.

HKT-SS (06823) sold approximately US$209 million for 9% equity interest in Regional Link Telecom Services Holdings Limited.

CNBM(03323): Tianshan Materials(000877.SZ) is expected to have a net loss attributable to shareholders of approximately 7.291 billion yuan in 2025, an increase of approximately 9.16 times year-on-year.
SSY GROUP(02005): Upatinib has been approved by the China Food and Drug Administration for registration as an active pharmaceutical ingredient for use in marketed preparations.

HKT-SS (06823) sold approximately US$209 million for 9% equity interest in Regional Link Telecom Services Holdings Limited.

CNBM(03323): Tianshan Materials(000877.SZ) is expected to have a net loss attributable to shareholders of approximately 7.291 billion yuan in 2025, an increase of approximately 9.16 times year-on-year.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


